Authors

Latest:

Dr. Schulte on the PRECISION 1 Trial of Nab-Sirolimus in TSC1/2-Mutated Solid Tumors

Brian Schulte, MD, discusses the ongoing phase 2 PRECISION 1 basket trial evaluating the use of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring TSC1/2 mutations.

Tom Martin, MD

Latest:

Insights from IMS 2024 on Counseling Patients with Multiple Myeloma about CAR T-cell Therapy and Connecting to Referral Centers

Panelists discuss how community providers can implement strategies and utilize resources to effectively connect patients to referral centers for chimeric antigen receptor T-cell therapy, while addressing how to initiate conversations about the therapy and counsel patients regarding potential adverse events.

Jason Sicklick, MD, FACS

Latest:

Next-Generation Treatment Strategies for GIST: Evaluating Combination Therapies and Mutation-Specific Approaches

Experts discuss the preliminary results of the PEAK study on the combination of bezuclastinib and sunitinib in second-line gastrointestinal stromal tumors (GIST), its potential to address heterogeneous resistance mutations, and how mutation-specific, biomarker-driven approaches in ongoing trials like INSIGHT may shift the treatment paradigm compared with traditional line-of-therapy strategies.

William Jacot, MD, PhD

Latest:

Dr. Jacot on Ribociclib Dose Reduction in HR+/HER2– Advanced Breast Cancer

William Jacot, MD, PhD, discusses updated efficacy and safety results from the phase 2 AMALEE trial.

Robert E. Schoen, MD, MPH

Latest:

ctDNA as a Marker of Recurrence Risk in stage III CRC: The α-CORRECT Study

Dr. Robert E. Schoen presents findings from the α-CORRECT study, highlighting the potential of circulating tumor DNA (ctDNA) as a biomarker for recurrence risk assessment in patients with stage III colorectal cancer.

Bradley Corr, MD

Latest:

Dr Corr on the Rationale for Investigating Rucaparib Maintenance in Endometrial Cancer

Bradley R. Corr, MD, discusses a phase 2 study evaluating rucaparib maintenance therapy in patients with metastatic and recurrent endometrial cancer.

Larysa J. Sanchez, MD

Latest:

Navigating the Increasing Complexity of Therapeutic Sequencing for Relapsed/Refractory Multiple Myeloma

The treatment landscape of relapsed/ refractory multiple myeloma has undergone rapid changes over the past 2 decades, with over a dozen drug approvals by the FDA.

Michael R. Grunwald, MD, FACP

Latest:

Dr Grunwald on Monitoring Risk Factors for Disease Progression in PV

Michael R. Grunwald, MD, discusses the importance of monitoring risk factors associated with disease progression in patients with polycythemia vera.

Evan B. Shereck, MD, MEd

Latest:

Dr. Shereck Highlights a Day In the Life of an Attending Physician

Evan B. Shereck, MD, MEd, serves as professor of pediatrics, Division of Hematology and Oncology, School of Medicine; program director, Pediatric Hematology/Oncology Fellowship; associate director, Cancer Research Training, Knight Cancer Institute; and block co-director, Blood and Host Defense at Oregon Health & Science University. In this episode, she highlights the average work day as an attending physician.

John F. Lazar, MD

Latest:

Dr. Lazar on Risk Stratification for Chemotherapy and Adjuvant Therapy in Lung Cancer

John F. Lazar, MD, discusses risk stratification for chemotherapy and adjuvant therapy in lung cancer.

IU School of Medicine

Latest:

IU Cancer Researchers Refining Colorectal Cancer Classification, Identifying New Targets for Treatment Using Cutting-Edge, Single-Cell Technology

Analyzing nearly 500,000 single cells, researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center are refining how to classify colorectal cancer and identify new targets to develop effective therapies.

Peter Forsberg, MD

Latest:

Advice for Community Oncologists Treating Patients With R/R MM

Drs Lipe and Forsberg share advice for community oncologists and highlight unmet needs in the management of multiple myeloma.

David H. Aggen, MD, PhD

Latest:

Breaking Down the Data in Bladder Cancer With Drs Aggen, Grivas, and Shore

David H. Aggen, MD, PhD, Petros Grivas, MD, PhD, and Neal Shore, MD, FACS, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in bladder cancer presented during the 2025 ESMO Congress.

Kadrin Wilfong, MD

Latest:

Camidge and Wilfong on Making A Difference Through a Career in Continuing Medical Education

D. Ross Camidge, MD, PhD, and Kadrin Wilfong, MD discuss Wilfong's passion for continuing medical education (CME) and how CME events and resources can make a difference in the care of patients with cancer.

Daniel C. Danila, MD

Latest:

Dr. Danila on Examining Immunotherapy in Early-Stage Prostate Cancer

Daniel C. Danila, MD, discusses the rationale for examining immunotherapy in early-stage prostate cancer.

Antonia DePace

Latest:

From the Ground Up: Daniel G. Haller, MD, Gets Giants of Cancer Care Award in GI Cancer

Daniel G. Haller, MD, says he has relied on “cheerful serendipity” throughout his life and career.

S. Daniel Haldar, MD

S. Daniel Haldar, MD, is an assistant professor in the Department of Gastrointestinal Medical Oncology of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, and an adjunct assistant professor in the Department of Oncology at Johns Hopkins University School of Medicine

Latest:

Dr Haldar on the Future Directions for Evaluating NeoAg-VAX in Colorectal Cancer

S. Daniel Haldar, MD, explains the future directions for evaluating NeoAg-VAX in colorectal and pancreatic cancer.

Dickon Hayne, MD, FRCS, MBBS

Dickon Hayne, MD, FRCS, MBBS, is a professor of urology at The University of Western Australia Medical School, as well as a consultant urological surgeon and the head of Urology for the South Metropolitan Health Service in Perth.

Latest:

Dr Hayne on the Rationale for Evaluating Mitomycin Plus BCG vs BCG Alone in NMIBC

Dickon Hayne, MD, FRCS, MBBS, discusses the rationale for evaluating the addition of mitomycin to BCG in non–muscle-invasive bladder cancer.

Kevin Harrington, MD, PhD, FRCP, FRCR, FRSB

Latest:

HPV16-Targeted Immunotherapy Is Set to Personalize HNSCC Management: With Kevin Harrington, MD, PhD, FRCP, FRCR, FRSB

Dr Harrington discusses PDS0101 plus pembrolizumab in HPV16+ HNSCC and how the VERSATILE-003 trial may change the HNSCC treatment paradigm.

Dana B Cardin, MD, MSCI

Latest:

Dr Cardin on the Influence of Comorbidities on Treatment Selection in Pancreatic Cancer

Dana B Cardin, MD, MSCI, discusses the importance of identifying comorbidities and high-risk features when determining the optimal treatment approach for patients with pancreatic cancer.